Dec 2, 2021 7:00 am EST Acasti Pharma Announces Interim Data Meets All Primary Endpoints for Pivotal PK Study for GTX-104
Nov 24, 2021 8:30 am EST Acasti Pharma CEO to Participate in the Benzinga All Access Event on December 2nd
Nov 10, 2021 7:00 am EST Acasti Pharma Provides Business Update for the Second Quarter of Fiscal 2022
Nov 4, 2021 8:30 am EDT Acasti Pharma Schedules Second Quarter Fiscal 2022 Business Update Conference Call
Oct 6, 2021 8:30 am EDT Acasti Pharma Awarded Composition-of-Matter Patents for GTX-101 in Europe, China and Mexico and for GTX-102 in Japan
Sep 27, 2021 8:30 am EDT Acasti Pharma Announces Initiation of Pharmacokinetic Bridging Study for GTX-104, the Company’s Lead Drug Candidate for the Treatment of Subarachnoid Hemorrhage
Sep 22, 2021 8:30 am EDT Acasti Pharma Provides Update Following Acquisition of Grace Therapeutics and Regains Compliance with Nasdaq Listing Standards
Sep 14, 2021 8:30 am EDT Acasti Pharma to Present at the Oppenheimer Fall Healthcare Summit on September 21ˢᵗ